Cognition Therapeutics (NASDAQ:CGTX – Get Free Report) and Peak Bio (NASDAQ:PKBO – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.
Volatility and Risk
Cognition Therapeutics has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, Peak Bio has a beta of -0.55, indicating that its stock price is 155% less volatile than the S&P 500.
Insider & Institutional Ownership
23.4% of Cognition Therapeutics shares are owned by institutional investors. 23.8% of Cognition Therapeutics shares are owned by company insiders. Comparatively, 19.9% of Peak Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Cognition Therapeutics | N/A | -60.65% | -46.91% |
| Peak Bio | N/A | N/A | -103.78% |
Analyst Recommendations
This is a summary of recent ratings and price targets for Cognition Therapeutics and Peak Bio, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cognition Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Peak Bio | 0 | 0 | 1 | 0 | 3.00 |
Cognition Therapeutics presently has a consensus price target of $7.50, suggesting a potential upside of 387.01%. Peak Bio has a consensus price target of $15.00, suggesting a potential upside of 4,404.50%. Given Peak Bio’s higher probable upside, analysts plainly believe Peak Bio is more favorable than Cognition Therapeutics.
Earnings and Valuation
This table compares Cognition Therapeutics and Peak Bio’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cognition Therapeutics | N/A | N/A | -$21.40 million | ($0.86) | -1.79 |
| Peak Bio | $610,000.00 | 11.96 | -$13.09 million | N/A | N/A |
Peak Bio has higher revenue and earnings than Cognition Therapeutics.
Summary
Cognition Therapeutics beats Peak Bio on 5 of the 9 factors compared between the two stocks.
About Cognition Therapeutics
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.
About Peak Bio
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. Its lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is headquartered in Palo Alto, California.
Receive News & Ratings for Cognition Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognition Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
